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1321Epidemiological data demonstrate a prevalence as high as
19% in the general population and 29% in patients age >70
years of lower extremity peripheral arterial disease (PAD) in
the United States and Europe (1,2). Superﬁcial femoral artery
(SFA) stenoses and occlusions are the most common cause
of symptomatic PAD (3). Endovascular treatment of short
lesions has been recommended by the TransAtlantic Inter-
Society Consensus (TASC) and by the American Heart
Association (4,5). Randomized controlled trials (RCTs)See page 1328
polytetraﬂuoroethylene
ITT = intention-to-treat
PAD = peripheral arterial
disease
PTA = percutaneous
transluminal balloon
angioplasty
RCT = randomized controlled
trial
SFA = superﬁcial femoral
artery
TASC = TransAtlantic Inter-
Society Consensus
TLR = target lesion
revascularization
TPP = treatment
per-protocol
VIA = Viabahn
endoprosthesis
WIQ = walking impairment
questionnairecomparing percutaneous transluminal balloon angioplasty
(PTA) and primary stenting in short lesions of the SFA have
demonstrated the superiority of primary stent placement (6,7).
More recently, drug-eluting balloons and drug-eluting
stents have been evaluated in RCTs, although only in short
lesions (8–11). With advancing technologies, endovascular
recanalization of long lesions (TASC II classes C and D) is
technically feasible in a large percentage of patients (12), but
the durability of PTA of long SFA lesions remains poor
(13,14). Primary stent placement in long SFA lesions has
shown promising results in a single-arm study (15). However,
bare-metal stents (BMS) do not prevent neointimal hyper-
plasia, and the risk for in-stent restenosis and stent fracture
grows with lesion length (16). An expanded polytetraﬂuoro-
ethylene (ePTFE) covering of stents prevents in-growth of
neointimal tissue regardless of lesion length. Therefore, the use
of ePTFE-covered stents in long femoropopliteal artery lesions
may increase the patency rate. It has been demonstrated in
animal studies that immobilized heparin on ePTFE vascular
grafts may reduce platelet deposition and neointimal
hyperplasia (17,18).
To evaluate the hypothesis that heparin-bonded ePTFE-
covered stents are superior to BMS in patients with symp-
tomatic PAD and long SFA lesions, including the proximal
popliteal artery, the VIASTAR (Viabahn Endoprosthesis
With PROPATEN Bioactive Surface [VIA] Versus Bare
Nitinol Stent in the Treatment of Long Lesions in Super-
ﬁcial Femoral Artery Occlusive Disease) trial was initiated.
Methods
The VIASTAR trial is a prospective, randomized, single-
blind, multicenter study that was physician initiated. The
protocol was developed and conducted in accordance with the
International Conference on Harmonisation/Good Clinical
Practice Guideline and the Declaration of Helsinki (ISO
14155-1 and ISO 14155-2). It was approved by the local
ethics committees and registered at the ISRCTN Register.Medtronic-Ardian, and Covidien-ev3; and has received lecture fees from sanoﬁ-
aventis, CR Bard, J&J Cordis, Covidien-ev3, Boston Scientiﬁc, Straub Medical,
Invatec, Biotronik, and Pathway Medical. Dr. Mueller-Huelsbeck has served as
a consultant for Boston Scientiﬁc; workshop organizer and lecturer for Termuo; and
presented educational cases for Abbott Vascular. Dr. Funovics has received lecture feesAll patients had to give written
informed consent. Patients were
recruited in 7 European centers.
Randomization was done by using
numbered envelopes, and the
correct sequence was monitored
centrally. Data were recorded on
an electronic case report form;
monitoring was provided by the
coordination center for clinical
studies (Koordinierungszentrum
fuer Klinische Studien) of the
Medical University Vienna, and
12-month results of color-coded
Doppler ultrasound (CDUS)
examinations were anonymized
and blinded before review by
CoreLab Bad Krozingen (Bad
Krozingen, Germany).
The study hypothesis was that
the endovascular treatment of
symptomatic long SFA lesions
with a heparin-bonded Viabahn
endoprosthesis (VIA) or a BMS
carries equal risks for adverse
events within 30 days after
the index procedure, and the
12-month patency rate of the
heparin-bonded Viabahn endo-
prosthesis would be superior by
25%. The ePTFE covering of the Viabahn endoprosthesis
may avoid in-growth of neointimal tissue, and the heparin
bonding may contribute to the reduction of thrombosis and
neointimal hyperplasia.
The major inclusion criteria were symptomatic PAD in
the Rutherford-Becker clinical stage 2 to 5 (moderate to
severe claudication and critical limb ischemia), de novo
arteriosclerotic stenosis or occlusion of the SFA and prox-
imal popliteal artery 10 to 35 cm in length (TASC II classes
B, C, and D) (4), patent or successfully treated iliac artery
inﬂow, and outﬂow of at least 1 tibial artery. The major
exclusion criteria were untreated inﬂow lesions, any previous
stenting or surgery in the target artery, serum creatinine level
>2.5 mg/dl, septicemia, and known intolerance to heparin,
antithrombotic study medications, or contrast agents.
The primary safety endpoint was a composite of serious
procedural adverse events, including death, myocardial in-
farction, study limb amputation, and access site and treat-
ment site complications requiring surgery, blood transfusion,
or prolonged hospital stay within 30 days of the indexfrom Bolten Medical. Dr. Schoder has received lecture fees from J&J Cordis and
Biotronik. All other authors have reported that they have no relationships relevant to
the contents of this paper to disclose.
Manuscript received January 7, 2013; revised manuscript received May 3, 2013,
accepted May 7, 2013.
Table 1
Demographic and Clinical Characteristics of the
Patients
Characteristic VIA (n ¼ 72) BMS (n ¼ 69) p Value
Age (yrs) 68.85  8.59 69.44  8.96
Male 48 (67) 52 (75) 0.34
Smoker at baseline 50 (69) 48 (70) 0.87
Hypertension 60 (83) 58 (84) 0.91
Hyperlipidemia 49 (68) 47 (68) 0.86
Coronary heart disease 16 (22) 15 (22) 0.89
Diabetes 25 (35) 25 (36) 0.99
Renal failure 12 (17) 5 (7) 0.14
Antithrombotic treatment 60 (83) 59 (86) 0.90
Statin therapy 41 (57) 42 (61) 0.76
Antihypertensive therapy 20 (28) 22 (32)
Clinical stage of peripheral
artery disease*
0.72
Rutherford 2 13 (18) 11 (17)
Rutherford 3 48 (68) 43 (65)
Rutherford 4 2 (3) 5 (8)
Rutherford 5 8 (11) 7 (11)
Baseline ankle-brachial
indexy
0.58  0.17 0.58  0.16 0.94
Values are mean  SD or n (%). *Rutherford stages 2 and 3 correspond to intermittent claudi-
cation, stage 4 to ischemic pain while the patient is resting, and stage 5 to ischemic ulcers. yRatio
of the blood pressure in the lower legs to the blood pressure in the arms.
BMS ¼ bare-metal nitinol stent(s); VIA ¼ Viabahn endoprosthesis.
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1322procedure. The primary efﬁcacy endpoint was the primary
patency rate measured at 1 year post-procedure. Primary
patency was deﬁned as no evidence of restenosis 50% or
occlusion within the study lesion based on CDUS with
a peak systolic velocity ratio 2.5 and no target lesion
revascularization (TLR) within 12 months (19). Secondary
endpoints were clinical improvement according to the
Rutherford category at 1, 6, and 12 months, walking distance
according to the walking impairment questionnaire (WIQ),
change of the ankle-brachial Doppler index (ABI) at
discharge and 1, 6, and 12 months, secondary patency, and
freedom from TLR.
The intervention was performed percutaneously with an
antegrade or crossover femoral artery access under local
anesthesia. Successful wire traversal of the target lesion was an
entry criterion for the study. Angiography of the target lesion
was performed in 2 planes before and after intervention. VIA
and BMS were inserted through a 6- or 7-F sheath. In the
VIA group, the Viabahn endoprosthesis (WL Gore, Flag-
staff, Arizona) with the contoured proximal edge and
heparin-bonded surface (PROPATEN Bioactive Surface)
was used. The BMS used were the Life-Stent (BARD
Peripheral Vascular, Inc., Tempe, Arizona), the Protégé
EverFlex Stent (ev3 Inc., Plymouth, Minnesota), and the
SMART-Control Stent (Cordis Corporation, Johnson &
Johnson,Warren, Massachusetts). These stents were selected
because of reported patency rates 80% at 1 year (7,20,21).
The BMS choice was at the operators’ discretion.
As study medication, all patients received 5,000 IU of
heparin during the procedure. After treatment, patients were
to take 100 mg of aspirin daily for life and 75 mg of clopi-
dogrel (Plavix, Sanoﬁ, Hoechst, Germany) daily for at least
6 months. Most patients started taking clopidogrel 1 or 2 days
before the index procedure; for those who did not, a loading
dose of 300 mg was given before or during the intervention.
The follow-up patient visits were scheduled at discharge
and 1, 6, and 12 months; if patients were symptomatic, these
visits included physical examination,WIQ, ABI, and CDUS.
In addition, peripheral computed tomography angiography
was performed at 12 months in a study subcohort.
Statistical analysis. It was calculated that 140 patients
would need to be enrolled for the study to have a statistical
power of 80% to detect an absolute difference of patency of
25% at 12 months. A 2-sided p value of 0.05 was considered
to indicate statistical signiﬁcance. Analysis of the data for the
primary and secondary patency rate, and the freedom from
TLR, was performed according to the intention-to-treat
(ITT) group and the treatment per-protocol (TPP) group.
Primary patency, secondary patency, and freedom from TLR
rates were calculated by using Kaplan-Meier product-limit
estimation, and the log-rank test was used to test for dif-
ferences between groups. Hazard ratios for primary patency
were calculated from a Cox proportional hazards regression
model accounting for treatment group and stented length.
Metric variables were described by mean  SD, and the
equality between the treatment groups was analyzed by usingStudent t tests. Categorial variables were described by
absolute and relative frequencies, and the homogeneity of
distributions between the 2 treatment groups was analyzed
by using chi-square tests or, if the test assumption was
violated, by the Fisher exact test. Descriptive statistics were
calculated for the ITT data. Calculations were performed by
using SAS version 9.3 (SAS Institute, Inc., Cary, North
Carolina).
Results
Study patients. From March 2009 to March 2011, a total
of 141 patients (100 men, 41 women; mean age 69  9
years; age range 47 to 90 years) were included. Demographic
and clinical characteristics were similar, with no signiﬁcant
differences between groups, except in length of the stented
segment (Tables 1 and 2). The mean lesion length was
19.0  6.3 cm in the VIA group and 17.3  6.6 cm in the
BMS group (p ¼ 0.13).
Acute technical success was achieved in all but 1 patient
who had a malposition of a BMS that needed surgical
removal followed by bypass. At discharge, ABI had signif-
icantly improved in the VIA and BMS groups, from 0.58 
0.17 and 0.58  0.16 (p ¼ 0.94) to 0.93  0.18 and 0.96 
0.14 (p ¼ 0.24), respectively.
Complications within 30 days after the index procedure
were recorded in 20 patients, 11 (15%) in the VIA group
and 9 (13%) in the BMS group (Table 2). Severe adverse
events within 30 days were observed once in each group:
a pseudoaneurysm and hematoma (VIA group), which
needed surgery, and a malposition of the stent (BMS group),
which was removed surgically, followed by bypass (2 of 141
Table 2 Baseline Angiographic and Interventional Data
VIA (n ¼ 72) BMS (n ¼ 69) p Value
Length of target lesion (mm) 189.8  63 173.2  66 0.13
Length of stented segment
(mm)
236.8  77 203.1  77 0.01
Target vessel diameter (mm) 6.08  0.6 6.25  0.7 0.88
Target vessel diameter (mm) 6.08  0.6 6.25  0.7 0.88
Occlusion 56 (79) 46 (70) 0.21
Target-lesion calciﬁcation* 0.15
None or mild 16 (23) 12 (17)
Moderate 44 (62) 34 (49)
Severe 11 (15) 19 (28)
Not applicable 4 (6)
TASC II classy 0.09
TASC A 0 2 (3)
TASC B >10 cm 20 (28) 29 (42)
TASC C 18 (25) 16 (23)
TASC D 34 (47) 22 (32)
No. of crural runoff vessels 0.96
3 32 (44) 29 (42)
2 28 (39) 27 (40)
1 10 (14) 10 (14)
0 2 (3) 3 (4)
No. of implants 0.04
0 2 (3) 0 (0)
1 18 (26) 29 (42)
2 41 (57) 36 (52)
3 11 (15) 4 (6)
Adverse events 11 (15) 9 (13) 0.77
Peripheral embolization 4 1
Hematoma 2 2
Pseudoaneurysm 1 0
Other 3 2
Death 0 0
Study limb amputation 0 0
Severe adverse events 1 (1.4) 1 (1.4) 1.0
ABI before discharge 0.93  0.18 0.96  0.14 0.24
Values are mean  SD or n (%). *Calciﬁcation was assessed by the investigator. yTransAtlantic
Inter-Society Consensus (TASC) II classiﬁcation is a lesion classiﬁcation according to the Inter-
Society Consensus for the Management of Peripheral Arterial Disease.
Abbreviations as in Table 1.
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1323[1.4% for both groups]). There were no deaths, myocardial
infarctions, or study limb amputations. Thus, the hypothesis
of the primary safety endpoint was met.
Follow-up. Six patients in each group had to be excluded
from ITT analysis because of major protocol violations: 6
due to screening failure (patients with lesions <10 cm and
>35 cm, and/or no tibial artery run-off), 4 due to incorrect
treatment (PTA only without any device placement, “spot
stenting” with <50% covering of the lesion after PTA),
1 who did not take any of the antithrombotic study medi-
cation, and 1 patient withdrew the informed consent after
discharge (Fig. 1). Of the 141 randomized patients (ITT),
129 patients (VIA 66; BMS 63) were available for the TPP
analysis. Causes for exclusion from ITT analysis are shown in
Figure 1. At 12 months, 63 of 72 VIA patients and 54 of
69 BMS patients were available for follow-up and 57 of
66 VIA patients and 52 of 63 BMS patients for TPP analysis.
At 1 year, the primary patency rate of all patients,
including those with major protocol violations (ITT), was
70.9% (95% conﬁdence interval [CI]: 0.58 to 0.80) versus
55.1% (95% CI: 0.41 to 0.67; log-rank test p ¼ 0.11) in the
VIA versus BMS group, respectively. In patients treated
according to the study protocol (TPP), 50% restenoses
were observed in 9 versus 22 patients and occlusions in 6
versus 4 patients in the VIA versus BMS group. Four of 6
VIA occlusions and 2 of 4 BMS occlusions occurred within
the ﬁrst 6 months despite double antiplatelet therapy. The
remaining occlusions occurred between 6 and 12 months
with aspirin medication only. The VIA occlusions were
treated in 3 patients by ﬁbrinolysis and in the other 3
patients by bypass surgery. One patient with an acutely
thrombosed VIA presented with acute limb ischemia. The 4
BMS occlusions were treated in 2 patients (1 bypass, 1
ﬁbrinolysis) and remained untreated in the other 2 patients.
In the 9 relevant (50%) VIA restenoses, edge stenosis at
the proximal or distal end was observed. In the 22 relevant
(50%) restenoses of BMS, diffuse instent restenosis was
seen most commonly, but edge stenoses were observed as
well. Therefore, at 1 year in patients treated according to the
study protocol, the primary patency rate (TPP) was 78.1%
(95% CI: 0.65 to 0.86) versus 53.5% (95% CI: 0.39 to 0.65;
log-rank test p ¼ 0.009) in the VIA versus BMS group,
respectively (Table 3, Figs. 2A and 2B). Thus, within the
ﬁrst year after the index procedure, the risk of binary
restenosis, occlusion, and TLR was 2.23 (95% CI: 1.15 to
4.35) times more likely when using a BMS. The hazard ratio
of BMS versus VIA calculated from a multiple Cox
proportional hazards model accounting for treatment group
and length of treated segment was 2.71 (95% CI: 1.36 to
5.39). Length of stented segment was included in the model
because signiﬁcant differences in this variable were observed
between treatment groups. Freedom from clinically driven
TLR was 84.6% (95% CI: 0.72 to 0.91) in the VIA group
versus 77.0% (95% CI: 0.63 to 0.85) in the BMS group at
1-year follow-up (log-rank test p ¼ 0.37). The secondary
patency rate (TPP) after TLR and bypass surgery was 89.9%(95% CI: 0.78 to 0.95) versus 75.2% (95% CI: 0.61 to 0.84)
in the VIA versus BMS group (log-rank test p ¼ 0.058).
A stratiﬁed analysis was performed to evaluate the effect
of TASC classiﬁcation and lesion length on primary
patency. At 12 months, patients with long lesions (20 cm,
TASC class D) had a signiﬁcantly higher primary patency
rate when treated with Viabahn endoprosthesis at ITT
analysis (VIA 71.3% [95% CI: 0.53 to 0.83]; BMS 36.8%
[95% CI: 0.17 to 0.57]; log-rank test p ¼ 0.01) and at TPP
analysis (VIA 73.3% [95% CI: 0.54 to 0.85]; BMS 33.3%
[95% CI: 0.13 to 0.54]; log-rank test p ¼ 0.004) (Figs. 3A
and 3B). In the group with lesion length <20 cm, a trend
toward higher patency rate after VIA was seen (VIA 86.4%;
BMS 63.0%), but the difference was not signiﬁcant (log-
rank test p ¼ 0.106). In a Cox proportional hazards
regression model, sex, clinical stage according to the Ruth-
erford category, diabetes, renal failure, calciﬁcation severity,
Table 3 Outcomes in Study Patients at 12 Months Follow-Up
ITT Analysis
VIA
(n ¼ 63/72) 95% CI
BMS
(n ¼ 54/69) 95% CI p Value
Restenosis 13 24
PSVR in >50% stenosis 2.72  1.29 3.25  2.03 0.54
Reocclusion 8 6
Primary patency rate (all) 70.9% 0.58–0.80 55.1% 0.41–0.67 0.11
Primary patency rate (lesion 20 cm) 71.3% 0.53–0.83 36.8% 0.17–0.57 0.01
TLR 13 16
ABI (mean) 0.93  0.23 0.85  0.23 0.1
TPP Analysis
VIA
(n ¼ 57/66) 95% CI
BMS
(n ¼ 52/63) 95% CI p Value
Restenosis 9 22
Reocclusion 6 4
Primary patency rate (all) 78.1% 0.65–0.86 53.5% 0.39–0.65 0.009
Primary patency rate (lesion 20 cm) 73.3% 0.54–0.85 33.3% 0.13–0.54 0.004
TLR 9 13
Freedom from TLR rate 84.6% 0.72–0.91 77.0% 0.63–0.85 0.37
Secondary patency rate 89.9% 0.78–0.95 75.2% 0.61–0.84 0.058
ABI (mean) 0.94  0.23 0.85  0.23 0.048
Rutherford category
improvement 1 (%)
84 84
Walking distance
(according to WIQ) (m)
785.8 565.9 m 0.17
Values are n, mean  SD, or %.
ABI ¼ ankle-brachial index; CI ¼ conﬁdence interval; ITT ¼ intention-to-treat; PSVR ¼ peak systolic velocity ratio; TLR ¼ target lesion revascularization;
TPP ¼ treatment per-protocol; WIQ ¼ walking impairment questionnaire; other abbreviations as in Table 1.
Figure 1 Randomization and Follow-Up of Study Patients
*Screening failures: patients with lesions <10 cm and >35 cm, no tibial run-off. yIncorrect treatment: percutaneous transluminal balloon angioplasty (PTA) only
without any device placement, “spot stenting” with <50% covering of the lesion after PTA. ITT ¼ intention-to-treat; TPP ¼ treatment per-protocol.
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Figure 3 Patency Rate of Lesions 20 cm
Primary patency of VIA (red) versus BMS (black) in superﬁcial femoral artery
lesions of patients with symptomatic peripheral arterial disease and lesions 20
cm. (A) ITT: at 12 months VIA: 71.3% (95% CI: 0.53 to 0.83) versus BMS: 36.8%
(95% CI: 0.17 to 0.57; log-rank test p ¼ 0.01). (B) TPP: at 12 months VIA: 73.3%
(95% CI: 0.54 to 0.85) versus BMS: 33.3% (95% CI: 0.13 to 0.54; log-rank test
p ¼ 0.004). Abbreviations as in Figures 1 and 2.
Figure 2 Patency Rate of All Lesions
Primary patency of Viabahn endoprosthesis (VIA) (red) versus bare-metal stent
(BMS) (black) in the superﬁcial femoral artery lesions of patients with symptom-
atic peripheral arterial disease. (A) ITT: at 12 months VIA 70.9% (95% conﬁdence
interval [CI]: 0.58 to 0.80) versus BMS 55.1% (95% CI: 0.41 to 0.67; log-rank test
p ¼ 0.11). (B) TPP: at 12 months VIA 78.1% (95% CI: 0.65 to 0.86) versus BMS
53.5% (95% CI: 0.39 to 0.65) (hazard ratio 2.23 [95% CI: 1.14 to 4.34]; log-rank
test p ¼ 0.009). Abbreviations as in Figure 1.
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1325and stenosis versus occlusion had no signiﬁcant inﬂuence on
outcomes.
The ABI (at discharge 0.93  0.18 vs. 0.97  0.14) of the
VIA group versus BMS group was 0.96  0.19 vs. 0.98 
0.14 [p ¼ NS], 0.94  0.24 vs. 0.87  0.24, and 0.94 
0.23 vs. 0.85  0.23 [p < 0.05] at 1, 6, and 12 months,
respectively (Table 3). An improvement by 1 Rutherford
category was reported in 84.0% in both groups at 12 months
(Fig. 4A). The mean walking distance according to the
WIQ was 136.3 m versus 115.1 m (p ¼ 0.13) at baseline and
785.8 m versus 565.9 m (p ¼ 0.17) in the VIA versus BMS
cohort at 12 months, respectively (Fig. 4B). These data
include patients after TLR and bypass.
Discussion
The purpose of the current study was to evaluate whether
a heparin-bonded ePTFE-covered endoprosthesis such asthe VIA is superior to bare-metal nitinol stents (BMS) in
patients with symptomatic PAD and long lesions of the
SFA and proximal popliteal artery. The ITT analysis did not
show a signiﬁcant difference but a trend in favor of the
heparin-bonded ePTFE-covered endoprosthesis (VIA 71%;
BMS 55%; log-rank test p ¼ 0.11). However, it was ﬂawed
by major protocol deviations in 8.5% of the patients. In the
TPP analysis, the Viabahn endoprosthesis showed a primary
patency rate of 78.1% versus 53.5% (p ¼ 0.009) for BMS at
12 months. Thus, within the ﬁrst year after the index
procedure, the risk of a binary restenosis, occlusion, and
TLR was 2.23 times more likely when using a BMS. This
conﬁrmed the original study hypothesis. The fact that the
TPP was signiﬁcantly at odds with the ITT analysis testiﬁes
that the rate of protocol violations was high and diluted the
statistical power. In lesions 20 cm (TASC class D), the
12-month patency rate was signiﬁcantly higher in VIA
patients in the ITT analysis (VIA 71.3% vs. BMS 36.8%;
Figure 4 Clinical Improvement
Categorized according to (A) Rutherford category and (B) walking distance (in
meters) according to the walking impairment questionnaire (WIQ) of the VIA versus
BMS in superﬁcial femoral artery lesions of patients with symptomatic peripheral
arterial disease. Relative frequencies are displayed as stacked bar plots. Range is
between grade 3 (indicating markedly improved) and –3 (indicating markedly
worsening). Abbreviations as in Figure 2.
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1326p ¼ 0.01) and the TPP analysis (VIA 73.3% vs. BMS
33.3%; p ¼ 0.004). Compared with baseline, ABI was
improved in both study cohorts with a higher ABI in the
Viabahn cohort of 0.94  0.23 versus a BMS ABI of 0.85 
0.23 (p < 0.05) at 12 months. Thus, objective parameters
showed a signiﬁcant beneﬁt. However, this improved
primary patency and ABI for the Viabahn endoprosthesis
group did not translate into a signiﬁcant reduction of clin-
ically driven TLR at 12 months (84.6% after Viabahn
endoprosthesis versus 77.0% after BMS; log-rank test
p ¼ 0.37). The relatively low clinically driven TLR rate in
the BMS group in relation to the high rate of instent
restenosis is difﬁcult to explain. One could argue that in-
stent restenosis in BMS still enables collateral ﬂow through
side branches, which may mitigate symptoms. However,
70% of the lesions in the BMS group were total occlusions
without side branches. The lower TLR rate may be due to
the slow progressive narrowing of the stent lumen due to
diffuse intimal hyperplasia in BMS. An additional post-
interventional exercise effect may have caused less obvious
recurrence of claudication. In the VIA group, the recurrence
was in one-third of the patients due to a total thromboticocclusion that caused a rapid deterioration of the walking
distance. In 1 of 6 patients, the thrombotic occlusion caused
an acute limb ischemia. The number of occlusions in the
VIA group was higher (6 vs. 4); this ﬁnding, however, was
not signiﬁcant. The VIA occlusions were treated in 3
patients by ﬁbrinolysis and in the other 3 patients by bypass.
The observed mean walking distance according to the WIQ
was longer in the VIA cohort at 12 months but did not reach
statistical signiﬁcance (785.8 m vs. 565.9 m; p ¼ 0.17). The
clinical improvement of 1 according to the Rutherford
classiﬁcation was 84.0% in both groups. However, the re-
ported ABI, walking distance, and clinical improvement are
parameters that correspond to the secondary patency rate
because they also include patients after TLR and bypass.
The endovascular treatment of PAD has the advantages
of low morbidity and mortality rates, and early recovery, and
it can be done as an outpatient procedure. BMS, drug-
eluting stents, and drug-eluting balloons have demon-
strated their superiority over plain PTA in short lesions only
(6–11). However, a prospective RCT for long lesions
focusing on various endovascular techniques has not yet been
published. In a prospective single-arm study with BMS in
long SFA lesions, 1-year freedom from TLR was reported in
68.2% (15). This ﬁnding was even lower than the freedom of
BMS from TLR in the current study (77%). The freedom
from TLR in the Viabahn arm of this study was 85%.
Bypass surgery with venous conduits must still be
considered as the gold standard when comparing primary
patency rates. However, considering the high secondary
patency rate of 89.9% in the Viabahn arm of this study, it
was demonstrated that similar results compared with surgery
could be achieved at a low procedural risk. In the current
study, the rate of severe complications requiring surgery or
prolonged hospital stay was 1.4%, and no deaths or study
limb amputations were observed. Thus, the overall risk
compared with surgery seems to be less (3,22). In the event
that no vein is available or that the vein should be preserved
for aorto-coronary bypass surgery, the 1-year patency rate
after synthetic graft femoropopliteal above-knee bypass
drops to 76%, as has been shown in a recent RCT (23).
Covered stents have the advantage of no in-growth of
neointimal tissue, which is the drawback of BMS. However,
graft thrombosis as disadvantage has been observed. In this
study, the Viabahn endoprosthesis with the heparin-bonded
surface (PROPATEN bioactive surface) was used (24,25).
The stably bound, endpoint immobilized heparin at the inner
surface of the ePTFE graft has been shown in the Scandina-
vian Propaten trial to signiﬁcantly prolong the primary patency
rate to 86.4% for heparin-bonded ePTFE grafts versus 79.9%
for plain ePTFE grafts (p¼ 0.043) at 1 year (26). All patients
were on antiplatelet medication with aspirin 100 mg daily
for life and clopidogrel 75 mg daily for at least 6 months,
which may be necessary to achieve a low thrombosis rate.
Study limitations. Twelve (8.5%) of the 141 patients had
a major protocol violation. There were 6 violations in each
study arm, and they were randomly distributed.
JACC Vol. 62, No. 15, 2013 Lammer et al.
October 8, 2013:1320–7 Covered vs. BMS for Complex SFA Lesions
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RCT in symptomatic PAD patients and endovascular
treatment of long femoropopliteal artery lesions. Clinical
and imaging endpoints were both considered, and both
study endpoints were met.
Conclusions
The clinical implication of the current study is that it
demonstrates, when treating PAD in patients with long
diffuse femoropopliteal artery disease, heparin-bonded
ePTFE-covered stents yield clinical and patency beneﬁts
compared with BMS.Acknowledgments
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